Study Serum Concentration of BP180 Glycoproteins in Multiple Sclerosis Patients and in Control Group in AL Zahra Hospital

Document Type : Original Article(s)

Authors

1 Professor of Pathology, Department of Pathology, School of Medicine, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

2 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i838.1461

Abstract

Background: Multiple sclerosis is an autoimmune disease in which a demyelination process occurs, leading to disorders of nerve signal transmission. Researchers identified a significant relationship between neurological diseases and serum glycoprotein concentrations. In this regard, this study aimed to determine the serum concentration of glycoprotein BP180 in patients with multiple sclerosis and in the control group at Al-Zahra Hospital (S).
Methods: In this cross-sectional study conducted in 1401 at the Isfahan Super specialty Hospital, 70 participants were enrolled and divided into two groups of MS patients (40 people) and a healthy control group (30 people). A researcher-made questionnaire was provided to them, collecting information related to age, past disease history, etc. Then, BP180 autoantibody was tittered using Euro immunoassay kits (made in Europe) by ELISA. Independent t-test and chi-square were used to analyze the data.
Findings: Mean BP180 level was measured as 33.22 IU/dL in the case group and 11.91 IU/dL in the control group. BP180 level was significantly higher in the MS group. (P<0.0001).
Conclusion: Overall, our results in favor to most of articles reports that BP180 autoantibody is significantly higher in MS patients rather than the normal population. This may be the possible explanation for the strong association of MS and BP.

Highlights

Azar Baradaran: Google Scholar

Keywords

Main Subjects

References

  1. Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Curr Opin Neurol 2018; 31(6): 752-9.
  2. Lassmann H. Multiple sclerosis pathology. Cold Spring Harb Perspect Med 2018; 8(3): a028936.
  3. Leray E, Moreau T, Fromont A, Edan G. Epidemiology of multiple sclerosis. Rev Neurol (Paris) 2016; 172(1): 3-13.
  4. Liu Y, Li L, Xia Y. BP180 is critical in the autoimmunity of bullous pemphigoid. Front Immunol 2017; 8: 1752.
  5. Van Beek N, Lüttmann N, Huebner F, Recke A, Karl I, Schulze FS, et al. Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol 2017; 153(1): 30-8.
  6. Tuusa J, Lindgren O, Tertsunen H-M, Nishie W, Kokkonen N, Huilaja L, et al. BP180 autoantibodies target different epitopes in multiple sclerosis or Alzheimer’s disease than in bullous pemphigoid. J Invest Dermatol 2019; 139(2): 293-9.
  7. Oya K, Watanabe R, Konishi R, Inoue S, Nakamura Y, Ishitsuka Y, et al. Possible involvement of IgE antibody in epidermolysis bullosa acquisita: detection and correlation. Eur J Dermatol 2019; 29(2): 210-2.
  8. Försti AK, Huilaja L, Schmidt E, Tasanen K. Neurological and psychiatric associations in bullous pemphigoid—more than skin deep? Exp Dermatol 2017; 26(12): 1228-34.
  9. Varpuluoma O, Jokelainen J, Försti A-K, Timonen M, Huilaja L, Tasanen K. Dermatitis herpetiformis and celiac disease increase the risk of bullous pemphigoid. J Invest Dermatol 2019; 139(3): 600-4.
  10. Bech R, Kibsgaard L, Vestergaard C. Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing litterature. Front Med (Lausanne) 2018; 5: 238.
  11. Schmidt E, Della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011; 29(3): 427-38, viii-ix.
  12. Prüßmann W, Prüßmann J, Koga H, Recke A, Iwata H, Juhl D, et al. Prevalence of pemphigus and pemphigoid autoantibodies in the general population. Orphanet J Rare Dis 2015; 10: 63.
Journal of Isfahan Medical School
Volume 43, Issue 838
2nd Week, January
January and February 2026
Pages 1461-1464

Files

History

  • Receive Date: 21 April 2025
  • Accept Date: 31 August 2025

Share

How to cite

Statistics